The term was partly inspired by the preamble to the World Health Organization’s 1948 constitution which said: “Health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity.” It was initially brought to use in the US by Halbert L. Dunn, M.D. in the 1950s; Dunn was the chief of the National Office of Vital Statistics and discussed “high-level wellness,” which he defined as “an integrated method of functioning, which is oriented toward maximizing the potential of which the individual is capable.” The term "wellness" was then adopted by John Travis who opened a "Wellness Resource Center" in Mill Valley, California in the mid-1970s, which was seen by mainstream culture as part of the hedonistic culture of Northern California at that time and typical of the Me generation. Travis marketed the center as alternative medicine, opposed to what he said was the disease-oriented approach of medicine. The concept was further popularized by Robert Rodale through Prevention magazine, Bill Hetler, a doctor at University of Wisconsin–Stevens Point, who set up an annual academic conference on wellness, and Tom Dickey, who established the Berkeley Wellness Letter in the 1980s. The term had become accepted as standard usage in the 1990s.
Diabetes Relief provides the gold standard for diabetes care by employing its patent-pending protocol using FDA-approved drugs and devices that are covered and recognized by most insurance providers. Upon receipt of approval from Diabetes Relief, physicians can apply for affiliation to become a licensed Diabetes Healthcare Center. Assistance with all aspects of build-out of the care facility and hiring and training staff is provided to approved practices.
Big pharma are in the early stages of developing their own cell therapy approaches for diabetes. Novo Nordisk, one of the largest providers of diabetes treatments, is bidding for stem cells and an encapsulation device, stating that the first clinical trial could take place in the “next few years.” Sanofi, also a big name in diabetes, is working with the German Evotec in a beta cell replacement therapy for diabetics.
No matter the size of your organization—a WELCOA membership provides you with training and tools you need to change organizational culture, increase engagement, contain costs, and improve the lives of your employees. Ideal for workplace wellness and human resource professionals, benefits consultants and brokers—our solution encourages organizations to fuse knowledge and engage all team members to design your own highly personalized approach.
Findings from the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) have clearly shown that aggressive and intensive control of elevated levels of blood sugar in patients with type 1 and type 2 diabetes decreases the complications of nephropathy, neuropathy, retinopathy, and may reduce the occurrence and severity of large blood vessel diseases. Aggressive control with intensive therapy means achieving fasting glucose levels between 70-120 mg/dl; glucose levels of less than 160 mg/dl after meals; and a near normal hemoglobin A1c levels (see below).
Certain drugs may also help to control pain. These include anti-inflammatory medicines such as ibuprofen, aspirin, naproxen, indomethacin, and many others. While some of these are sold over the counter, they can have side effects, most notably gastrointestinal bleeding. A newer anti-inflammatory, celecoxib (Celebrex), may have fewer gastrointestinal side effects.
The earliest surviving work with a detailed reference to diabetes is that of Aretaeus of Cappadocia (2nd or early 3rd century CE). He described the symptoms and the course of the disease, which he attributed to the moisture and coldness, reflecting the beliefs of the "Pneumatic School". He hypothesized a correlation of diabetes with other diseases, and he discussed differential diagnosis from the snakebite which also provokes excessive thirst. His work remained unknown in the West until 1552, when the first Latin edition was published in Venice.
Many people may not want to divulge their bathroom dramas to a doctor, or anyone, or may think that heartburn is common and no big deal. Everyone gets a tummy ache now and again, but if you have diabetes, GI symptoms may indicate that something is chronically wrong. “If it bothers you, it’s worth getting checked out,” says Bragg. With a proper diagnosis, you and your health care provider can come up with a plan to make your whole body feel a whole lot better.
That is the goal of Imcyse, a French company running a clinical trial with an immunotherapy designed to stop type 1 diabetes. Patients that have been diagnosed within the last 6 months, who still retain some insulin-producing cells, are given a treatment designed to make the immune system destroy the specific immune cells that are attacking insulin-producing cells. Results are expected later this year and will reveal whether the treatment has the potential to become a cure.
Innovation in technology is not just fuelling advances in diabetes treatments though. I know it will accelerate the path to the cure. And this is what unites people with type-1 diabetes, researchers, our charitable supporters and funders. I am convinced one day we will consign type 1 to the history books and no one will ever receive this life-changing diagnosis again.
In July, she received an overture from a well-known influencer-management platform called Speakr, on behalf of the DNA-testing company 23andMe. It was offering her $300 for a Facebook post. “Somebody really likes you! One of our brand partners is running a campaign and we think you’re a perfect fit,” read the email from Speakr, which Yu shared with The Atlantic.
Another French company, Valbiotis (FP:ALVAL), has developed the plant-based VALEDIA to reduce the risk of type 2 diabetes by treating patients with pre-diabetic symptoms. The product is based on the active ingredient TOTUM-63, a combination of five plant extracts that work synergistically to address several metabolic factors that play a role in diabetes development.
There is, in fact, no difference in meaning between preventive and preventative. Some, including William Safire in a 1993 On Language column, have suggested using preventive as an adjective and preventative as a noun, but both forms of the word have alternated freely as adjective and noun since they entered the language in the 17th century. Despite their introduction into English at roughly the same time (the Oxford English Dictionary dates preventive back to 1626 and preventative to 1655), preventive has won out as the preferred version.
Diabetes experts feel that these blood glucose monitoring devices give patients a significant amount of independence to manage their disease process; and they are a great tool for education as well. It is also important to remember that these devices can be used intermittently with fingerstick measurements. For example, a well-controlled patient with diabetes can rely on fingerstick glucose checks a few times a day and do well. If they become ill, if they decide to embark on a new exercise regimen, if they change their diet and so on, they can use the sensor to supplement their fingerstick regimen, providing more information on how they are responding to new lifestyle changes or stressors. This kind of system takes us one step closer to closing the loop, and to the development of an artificial pancreas that senses insulin requirements based on glucose levels and the body's needs and releases insulin accordingly - the ultimate goal.
People with full-blown type 2 diabetes are not able to use the hormone insulin properly, and have what’s called insulin resistance. Insulin is necessary for glucose, or sugar, to get from your blood into your cells to be used for energy. When there is not enough insulin — or when the hormone doesn’t function as it should — glucose accumulates in the blood instead of being used by the cells. This sugar accumulation may lead to the aforementioned complications.